36
Participants
Start Date
October 28, 2019
Primary Completion Date
January 14, 2020
Study Completion Date
January 14, 2020
Belimumab for IV
Belimumab will be available as white to off-white lyophilized cake at a unit dose strength of 400 mg to be reconstituted and diluted in normal saline to obtain 200 mg per dose.
Belimumab for SC
Belimumab will be available as clear to opalescent, colorless to pale yellow sterile solution at unit dose strength of 200 mg/milliliter (mg/mL) for SC injection in a single-use, prefilled syringe contained within an auto-injector device.
GSK Investigational Site, Shanghai
Lead Sponsor
GlaxoSmithKline
INDUSTRY